Celyad Oncology S.A.
CYAD
Rang in aandelen
#31623
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aandeelprijs
$0.25502336
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$12.05M
Verandering (1 dag)
0.47%
Verandering (1 jaar)
-45.74%
Land
BE
Handel Celyad Oncology S.A. (CYAD)
Categorie
Healthcare
Marktkapitalisatie van Celyad Oncology S.A.(CYAD)
Marktkapitalisatie: $12.05M
Vanaf October 2026 heeft Celyad Oncology S.A. een marktkapitalisatie van $12.05M. Dit maakt Celyad Oncology S.A. volgens onze gegevens het 31623rd meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van Celyad Oncology S.A. van 2015 tot 2026
CYAD vergeleken met de top 5 populairste stocks
